Consolidated and Combined Statements of Shareholders' Equity - USD ($) $ in Thousands |
Total |
Separation |
Public Offerings |
Registered Direct Offerings |
Equity Facility |
Recro |
Parent Company Net Investment |
Parent Company Net Investment
Recro
|
Common Stock |
Common Stock
Separation
|
Common Stock
Public Offerings
|
Common Stock
Registered Direct Offerings
|
Common Stock
Equity Facility
|
Additional Paid in Capital |
Additional Paid in Capital
Separation
|
Additional Paid in Capital
Public Offerings
|
Additional Paid in Capital
Registered Direct Offerings
|
Additional Paid in Capital
Equity Facility
|
Additional Paid in Capital
Recro
|
Accumulated Deficit |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance at Dec. 31, 2018 | $ (68,347) | $ (68,347) | ||||||||||||||||||
Stock-based compensation expense | 499 | $ 4,964 | $ 4,964 | $ 499 | ||||||||||||||||
Issuance of common stock | $ 94 | $ (94) | ||||||||||||||||||
Issuance of common stock, Shares | 9,350,709 | |||||||||||||||||||
Reclassification of parent company net investment | 33,480 | $ (33,480) | ||||||||||||||||||
Net transfer from parent company | 60,268 | 60,268 | ||||||||||||||||||
Contribution of cash by Recro Pharma, Inc. upon separation | 19,000 | 19,000 | ||||||||||||||||||
Separation related adjustments | (548) | (548) | ||||||||||||||||||
Net loss | (32,557) | $ (30,365) | (2,192) | |||||||||||||||||
Balance at Dec. 31, 2019 | (16,721) | $ 94 | 19,405 | (36,220) | ||||||||||||||||
Balance, Shares at Dec. 31, 2019 | 9,350,709 | |||||||||||||||||||
Stock-based compensation expense | 7,568 | $ 1,773 | 7,568 | $ 1,773 | ||||||||||||||||
Issuance of common stock | $ 1 | $ 14,973 | $ 21,696 | $ 3,612 | $ 1 | $ 77 | $ 71 | $ 4 | $ 14,896 | $ 21,625 | $ 3,608 | |||||||||
Issuance of common stock, Shares | 45,874 | 7,692,308 | 7,100,000 | 441,967 | ||||||||||||||||
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes | (475) | $ 7 | (482) | |||||||||||||||||
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes, Shares | 707,172 | |||||||||||||||||||
Warrants issued in connection with financing facility | 1,423 | 1,423 | ||||||||||||||||||
Exercise of warrants value | 5,593 | $ 221 | 5,372 | |||||||||||||||||
Exercise of warrants, Shares | 22,163,676 | |||||||||||||||||||
Warrant exchange value | 21,858 | $ 12 | 21,846 | |||||||||||||||||
Warrant exchange Shares | 1,186,774 | |||||||||||||||||||
Net loss | (76,100) | (76,100) | ||||||||||||||||||
Balance at Dec. 31, 2020 | $ (14,799) | $ 487 | $ 97,034 | $ (112,320) | ||||||||||||||||
Balance, Shares at Dec. 31, 2020 | 48,688,480 |
X | ||||||||||
- Definition Adjustments to additional paid in capital contribution of cash received upon separation. No definition available.
|
X | ||||||||||
- Definition Exercise of warrants shares. No definition available.
|
X | ||||||||||
- Definition Exercise of warrants value. No definition available.
|
X | ||||||||||
- Definition Net transfer from parent. No definition available.
|
X | ||||||||||
- Definition Reclassification of investment. No definition available.
|
X | ||||||||||
- Definition Separation-related adjustments. No definition available.
|
X | ||||||||||
- Definition Warrant exchange shares. No definition available.
|
X | ||||||||||
- Definition Warrant exchange value. No definition available.
|
X | ||||||||||
- Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. No definition available.
|
X | ||||||||||
- Definition Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. No definition available.
|
X | ||||||||||
- Definition Number of shares issued which are neither cancelled nor held in the treasury. No definition available.
|
X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|